NCT04396535 2025-11-17
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
Mayo Clinic
Phase 2 Terminated
Clinical Trials
78 trialsNCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04427072 2025-05-16
GeoMETry-III
Novartis
Phase 3 Terminated
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT05062980 2025-02-20
Acclaim-2
Genprex, Inc.
Phase 1/2 Terminated
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT03095612 2024-06-13
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT04171284 2024-02-09
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
Sinocelltech Ltd.
Phase 3 Terminated
NCT00617656 2024-01-30
BREC
Spanish Lung Cancer Group
Phase 3 Terminated
NCT03228186 2023-10-23
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT05106335 2023-08-16
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT05001724 2023-04-25
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2/3 Terminated
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT03041181 2022-07-11
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02460367 2022-04-06
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1 Terminated
NCT03990077 2021-12-10
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
Shanghai Kechow Pharma, Inc.
Phase 1 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT01741155 2021-10-13
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT02387216 2021-10-12
SHERLOC
Elevation Oncology
Phase 2 Terminated
NCT03256721 2021-02-08
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Fuzhou General Hospital
Phase 2 Terminated
NCT00738387 2020-12-24
ATTRACT-2
Novartis
Phase 3 Terminated
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT01646125 2019-07-24
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Novartis
Phase 2 Terminated
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT02346370 2019-02-08
PRIMAL
Halozyme Therapeutics
Phase 1 Terminated
NCT02766140 2019-01-18
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT01935947 2018-07-27
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT02393209 2018-02-07
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Takeda
Phase 1/2 Terminated
NCT02326285 2018-01-23
NeoIntercal
AIO-Studien-gGmbH
Phase 2/3 Terminated
NCT00356941 2017-11-29
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT00520845 2017-03-20
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00565227 2016-12-02
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT01798485 2016-07-01
Galaxy 2
Synta Pharmaceuticals Corp.
Phase 3 Terminated
NCT00766246 2016-04-19
Phase II Avastin Trial for Stage IIIB/IV NSCLC
Pharmatech
Phase 2 Terminated
NCT00345059 2016-01-14
DISTAL-2
National Cancer Institute, Naples
Phase 3 Terminated
NCT01348126 2015-11-05
GALAXY
Synta Pharmaceuticals Corp.
Phase 2/3 Terminated
NCT00983047 2015-08-27
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01282151 2015-07-14
TRAIL
Chonnam National University Hospital
Phase 3 Terminated
NCT00378404 2015-06-08
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
University of Kentucky
Phase 1 Terminated
NCT01038752 2015-05-21
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Optimum Therapeutics, LLC
Phase 2 Terminated
NCT00238615 2015-05-12
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
Stanford University
Phase 2 Terminated
NCT01714037 2015-04-08
HALO
Debiopharm International SA
Phase 1 Terminated